Quest Diagnostics (DGX) Tops Q3 EPS by 4c; raises guidance

Quest Diagnostics (NYSE: DGX) reported Q3 EPS of $2.30, $0.04 better than the analyst estimate of $2.26. Revenue for the quarter came in at $2.49 billion versus the consensus estimate of $2.43 billion.

GUIDANCE:

Quest Diagnostics sees FY2024 EPS of $8.85-$8.95, versus the consensus of $8.89. Quest Diagnostics sees FY2024 revenue of $9.8-9.85 billion, versus the consensus of $9.657 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
• ADARx Pharmaceuticals files for proposed IPO
• Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance